CARnitine in the palliative treatment of advanced PANcreatic cancer (CARPAN)
Completed
- Conditions
- Advanced pancreatic cancerCancerMalignant neoplasm of pancreas
- Registration Number
- ISRCTN83465351
- Lead Sponsor
- niversity Medicine Greifswald (Germany)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
1. Advanced pancreatic cancer (UICC Stage IV)
2. A Karnofsky Index larger than 60
3. Compliance
4. The consent to participate in the study
Exclusion Criteria
1. Patients were excluded with a Child-Pugh classification of liver failure greater than Class B
2. A known second malignant tumor
3. Oral or parenteral supplementation with omega-3-fatty acids
4. Treatment with Thalidomide or Infliximab
5. Mental or physical disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Influence of L-Carnitine on proinflammatory cytokine tumor necrosis factor (TNF)-alpha
- Secondary Outcome Measures
Name Time Method 1. Influence of L-Carnitine on <br>1.1. Other proinflammatory cytokines (IL 6, IL8, IL12)<br>1.2. C-reactive protein (CRP)<br>1.3. Malnutrition and cancer cachexia, cancer related fatigue syndrome<br>1.4. Mortality<br>1.5. Hospital stay